Burjeel to launch Project Nader to study, treat rare diseases in UAE

ABU DHABI / WAM

Burjeel Holdings has partnered with BridgeBio Pharma, a commercial-stage biopharmaceutical firm focussed on genetic diseases and cancers, to launch a new project to revolutionise the field of early diagnosis and treatment of rare diseases or disorders in the UAE and the region.
The two entities signed a preliminary, non-binding collaboration agreement establishing a mutual intention to work together on project ‘Nader’ (Needs Assessment and Therapeutics Development for Rare Diseases — ‘nader’ meaning ‘rare’ in Arabic). Genetic in origin, these often life-threatening or chronically debilitating diseases affect a small percentage of the population and are present throughout a person’s entire life, even if symptoms do not immediately appear. The partnership will launch operations in Abu Dhabi to conduct clinical trials and research, leveraging the emirate’s advanced infrastructure for innovation and life science.
Project ‘Nader’ aims to revolutionise the field of early diagnosis and treatment in order to improve patient outcomes. Both entities intend to collaborate on identifying patients with several rare diseases, including achondroplasia, hypochondroplasia, FGFR-driven craniosynostoses, autosomal dominant hypocalcaemia type 1, limb girdle muscular dystrophy type 2i, congenital adrenal hyperplasia, Canavan disease, propionic acidemia, methylmalonic acidemia, pantothenate kinase associated neurodegeneration, and others as mutually agreed.
Even though these rare diseases affect a small percentage of the population and can present with nonspecific signs and symptoms, they are often misdiagnosed or only diagnosed later in the disease course after severe complications manifest.
Accurate and early diagnosis are crucial to starting intervention promptly and avoiding disease progression. The project will also allow identification of patients who have been diagnosed but do not currently have access to cutting edge therapies or clinical trial options.
In the first phase of project ‘Nader’, the two entities intend to utilise innovative risk assessment algorithms that will be deployed through the healthcare provider’s secure internal data to identify patients at risk for specific rare diseases. Expectations for future phases of the project include analyses of vast amounts of data to identify patterns and markers associated with the diseases and generate personalised risk scores for patients, followed by genetic testing to confirm the diagnosis of identified potential patients. The project also aims to run awareness campaigns and education activities about such rare diseases, to further support the mapping activity and encourage local collaborations from other healthcare providers. Burjeel Holdings will deploy the project across its widespread hospitals and medical centres across the UAE as part of routine diagnostic care, with plans to expand the project through its  healthcare infrastructure.
Commenting on the project launch, Dr Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Centre at the Department of Health – Abu Dhabi (DoH), said, “As part of our ongoing efforts to advance early diagnosis and treatment, the DoH is proud to witness yet another leading partnership aimed at propelling transformative medicine to safeguard the health and well-being of community members.”
“Reinforcing Abu Dhabi’s position as a leading destination for life science and innovation, we remain committed to empowering healthcare providers in the Emirate with the means to lead research studies and conduct clinical trials to map out a path towards discovery and breakthrough healthcare in the Emirate and beyond. Similar initiatives translate the Department’s vision in securing health for all while accelerating healthcare outcomes for the benefit of the global community.”
Speaking on the partnership’s potential to transform the way rare diseases are identified, John Sunil, CEO of Burjeel Holdings, said, “Project ‘NADER’ marks a significant milestone in our commitment to delivering the best possible care to our patients. It brings together Burjeel’s expertise in healthcare delivery and outreach and BridgeBio’s vast expertise in delivering breakthrough therapies for rare diseases. By combining our strengths, we seek to address the challenges faced in identification of rare diseases, which often go undiagnosed until symptoms become severe. The project will enable early interventions whether in the form of established treatments or novel therapies.”
The first phase will aim to set the roadmap to providing novel treatment options for identified patients through clinical trials.